WINDTREE THERAPEUTICS INC /DE/
WINTWDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Lucinactant | Phase 2 | COVID-19 | - | - |
Istaroxime | Phase 2 | Cardiogenic Shock | - | - |
Frequently asked questions
What is in WINDTREE THERAPEUTICS INC /DE/'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in WINDTREE THERAPEUTICS INC /DE/'s (WINTW) pipeline across Phase 2. Its lead program is Lucinactant (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is WINDTREE THERAPEUTICS INC /DE/'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for WINDTREE THERAPEUTICS INC /DE/ (WINTW) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track WINTW biotech catalysts?→
Add WINTW to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow WINDTREE THERAPEUTICS INC /DE/'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.